Euroopa Liit - eesti - EMA (European Medicines Agency)

alfasigma s.p.a. - metüültioniiniumkloriid - colorectal neoplasms; colonoscopy - other diagnostic agents - lumeblue is indicated as a diagnostic agent enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

chanelle pharmaceuticals manufacturing limited - sevofluraan - valuvaigistid, üldine - dogs; cats - anesteesia indutseerimiseks ja säilitamiseks.

Euroopa Liit - eesti - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - afoxolaner - ektoparasiitsiidid süsteemseks kasutamiseks - koerad - ravi kirbu (ctenocephalides felis ja c.. canis) infestatsioonid. seda toodet saab kasutada kirbuallergia dermatiidi (fad) ravistrateegia osana.. ravi rist (dermacentor reticulatus, ixodes ricinus, rhipicephalus sanguineus) infestatsioonid. ravi demodicosis (põhjustatud demodex canis). ravi sarcoptic mange (põhjustatud sarcoptes scabiei var. canis).

Euroopa Liit - eesti - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - artriit, reumatoidartriit - immunosupressandid - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant võib kasutada monoteraapiana või kombinatsioonis metotreksaadiga. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

Eesti - eesti - Ravimiamet

olainfarm as - tsiprofloksatsiin - õhukese polümeerikattega tablett - 250mg 100tk; 250mg 20tk; 250mg 10tk

Eesti - eesti - Ravimiamet

olainfarm as - tsiprofloksatsiin - õhukese polümeerikattega tablett - 500mg 10tk; 500mg 20tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - artriit, reumatoidartriit - immunosupressandid - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 ja 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Eesti - eesti - Ravimiamet

takeda pharma as - fentanüül - transdermaalne plaaster - 25mcg 1h 3tk; 25mcg 1h 4tk; 25mcg 1h 8tk; 25mcg 1h 5tk; 25mcg 1h 16tk; 25mcg 1h 1tk; 25mcg 1h 2tk; 25mcg 1h 20tk; 25mcg 1h 10tk

Eesti - eesti - Ravimiamet

takeda pharma as - fentanüül - transdermaalne plaaster - 100mcg 1h 10tk; 100mcg 1h 8tk; 100mcg 1h 20tk; 100mcg 1h 4tk; 100mcg 1h 3tk; 100mcg 1h 5tk; 100mcg 1h 1tk; 100mcg 1h 16tk

Eesti - eesti - Ravimiamet

takeda pharma as - fentanüül - transdermaalne plaaster - 12mcg 1h 10tk; 12mcg 1h 5tk; 12mcg 1h 16tk; 12mcg 1h 8tk; 12mcg 1h 2tk; 12mcg 1h 1tk; 12mcg 1h 20tk; 12mcg 1h 4tk